A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Phase 1 Recruiting 300 enrolled Orca Biosystems, Inc.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study will evaluate the safety, tolerability, and efficacy of engineered donor grafts ("OrcaGraft"/"Orca-Q") in participants undergoing allogeneic hematopoietic cell transplant (alloHCT) transplantation for hematologic malignancies.

Timeline

Start: 2019-04-08
Primary completion: 2027-12
Completion: 2027-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	OrcaGraft	Cell therapy	—	—

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Summary

Timeline

Drugs

Indications